Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1947 Target Snapshot

Thyroid hormone receptor beta · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
6,368Compounds
140Assays
8Approved Drugs
1,051.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Thyroid hormone receptor beta shows approved-linked disease relevance led by non-alcoholic steatohepatitis. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P10828. Start with non-alcoholic steatohepatitis, then reuse UniProt P10828 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with non-alcoholic steatohepatitis, then reuse UniProt P10828 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 2 linked drugs
Open source guide
Disease program
non-alcoholic steatohepatitis

Thyroid hormone receptor beta shows approved-linked disease relevance led by non-alcoholic steatohepatitis. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with non-alcoholic steatohepatitis because it currently carries approved-linked support. Linked drugs include MB07811, RESMETIROM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Thyroid hormone receptor beta as ChEMBL target CHEMBL1947, mapped to UniProt P10828. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Thyroid hormone receptor beta
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1947
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P10828
Thyroid hormone receptor beta
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Thyroid hormone receptor beta is the right protein anchor across sources, using UniProt P10828 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why non-alcoholic steatohepatitis is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameThyroid hormone receptor beta
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP10828
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelThyroid hormone receptor beta
UniProt AccessionP10828
Component TypeProtein
Sequence Length461 aa

Thyroid hormone receptor beta

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Thyroid hormone receptor beta, mapped to UniProt P10828. Sequence length is 461 aa.

Mapped IDP10828
Review nameThyroid hormone receptor beta
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Thyroid hormone receptor beta shows approved-linked disease relevance led by non-alcoholic steatohepatitis. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
non-alcoholic steatohepatitis
2 linked drugs · 2 direct · 2 efficacy
Linked drugMB07811
Linked drugRESMETIROM
Approved-linked Approved
metabolic dysfunction-associated steatotic liver disease
1 linked drug · 1 direct · 1 efficacy
Linked drugRESMETIROM
Approved-linked Approved
non-alcoholic fatty liver disease
1 linked drug · 1 direct · 1 efficacy
Linked drugRESMETIROM
Late clinical Phase III
familial hypercholesterolemia
2 linked drugs · 2 direct · 2 efficacy
Linked drugEPROTIROME
Linked drugRESMETIROM
Clinical signal Phase II
Hypercholesterolemia
3 linked drugs · 3 direct · 3 efficacy
Linked drugEPROTIROME
Linked drugMB07811
Linked drugRESMETIROM
Clinical signal Phase II
Disorder of lipid metabolism
1 linked drug · 1 direct · 1 efficacy
Linked drugEPROTIROME
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with non-alcoholic steatohepatitis because it currently carries approved-linked support. Linked drugs include MB07811, RESMETIROM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasenon-alcoholic steatohepatitis
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

8
Approved
3
Phase III
9
Phase II
Assay Mix

Activity Type Distribution

IC50666.0
KI139.0
EC50215.0
KD31.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL291053 10.72 IC50 0.019 Clinical
CHEMBL124126 10.7 Ki 0.02 Preclinical
CHEMBL289343 10.6 IC50 0.025 Preclinical
CHEMBL125381 10.52 Ki 0.03 Preclinical
CHEMBL124205 10.4 Ki 0.04 Preclinical
CHEMBL3397339 10.4 Ki 0.04 Preclinical
CHEMBL41632 10.39 IC50 0.04074 Clinical
CHEMBL124126 10.25 IC50 0.05623 Preclinical
CHEMBL203777 10.22 Ki 0.06 Preclinical
CHEMBL203777 10.22 IC50 0.06 Preclinical
Distribution

pChEMBL Value Distribution

85
5.0
104
5.5
111
6.0
89
6.5
112
7.0
81
7.5
69
8.0
59
8.5
47
9.0
41
9.5
pChEMBL
Approved Drugs

Approved Drugs

RESMETIROM
CHEMBL3261331
Approved 2024
Properties Compare Identifier
ROXADUSTAT
CHEMBL2338329
Approved 2021
Properties Compare Identifier
AMIODARONE
CHEMBL633
Approved 1985
Properties Compare Identifier
LEVOTHYROXINE
CHEMBL1624
Approved 1982
Properties Compare Identifier
LIOTHYRONINE
CHEMBL1544
Approved 1956
Properties Compare Identifier
Assay Landscape

Assay Landscape

140
Total Assays
666
Tested Compounds
2
Assay Types
Binding — 104 assays, 666 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 51 347 7.6
cell-based format 48 165 7.0
assay format 4 153 5.8
cell-free format 1 1 7.2
Functional — 36 assays, 36 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 18 20 5.7
cell-based format 18 16 7.7

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine